[424B5] Celcuity Inc. Prospectus Supplement (Debt Securities)
CVM Form 4: On 28 Jul 2025 director Robert E. Watson was granted 4,000 stock options with a $8.20 exercise price. The options vest in three equal annual installments beginning one year after grant and expire 27 Jul 2035. No common shares were bought or sold, and the transaction is coded “A” (acquisition). After this award, Watson holds 27,266 derivative securities, all in direct ownership. The filing represents a routine equity-incentive grant intended to align the director’s interests with shareholders. Given the modest size relative to CEL-SCI’s share count, the event is unlikely to have a material impact on valuation or near-term dilution.
Modulo CVM 4: Il 28 luglio 2025 il direttore Robert E. Watson ha ricevuto 4.000 opzioni su azioni con un prezzo di esercizio di 8,20 $. Le opzioni maturano in tre rate annuali uguali a partire da un anno dopo la concessione e scadono il 27 luglio 2035. Non sono state acquistate o vendute azioni ordinarie, e la transazione è classificata come “A” (acquisizione). Dopo questo premio, Watson detiene 27.266 strumenti derivati, tutti di proprietà diretta. La comunicazione rappresenta una normale concessione di incentivi azionari volta ad allineare gli interessi del direttore con quelli degli azionisti. Data la dimensione contenuta rispetto al numero di azioni di CEL-SCI, l’evento probabilmente non avrà un impatto significativo sulla valutazione o sulla diluizione a breve termine.
Formulario CVM 4: El 28 de julio de 2025, el director Robert E. Watson recibió 4,000 opciones sobre acciones con un precio de ejercicio de $8.20. Las opciones se otorgan en tres cuotas anuales iguales que comienzan un año después de la concesión y vencen el 27 de julio de 2035. No se compraron ni vendieron acciones ordinarias, y la transacción está codificada como “A” (adquisición). Después de esta adjudicación, Watson posee 27,266 valores derivados, todos en propiedad directa. La presentación representa una concesión rutinaria de incentivos accionarios destinada a alinear los intereses del director con los de los accionistas. Dado el tamaño modesto en relación con el número de acciones de CEL-SCI, es poco probable que el evento tenga un impacto material en la valoración o en la dilución a corto plazo.
CVM 양식 4: 2025년 7월 28일, 이사 로버트 E. 왓슨은 행사가격 $8.20의 4,000주 스톡옵션을 부여받았습니다. 옵션은 부여일로부터 1년 후부터 3년에 걸쳐 동일한 비율로 권리가 확정되며, 2035년 7월 27일에 만료됩니다. 보통주는 매수 또는 매도되지 않았으며, 거래는 “A”(취득)로 분류됩니다. 이번 수여 이후 왓슨은 모두 직접 소유한 27,266개의 파생증권을 보유하게 되었습니다. 이 신고는 이사의 이해관계를 주주와 일치시키기 위한 일상적인 주식 인센티브 부여를 의미합니다. CEL-SCI의 주식 수에 비해 규모가 작아, 이번 사건이 평가나 단기 희석에 중대한 영향을 미칠 가능성은 낮습니다.
Formulaire CVM 4 : Le 28 juillet 2025, le directeur Robert E. Watson s’est vu attribuer 4 000 options d’achat d’actions à un prix d’exercice de 8,20 $. Les options sont acquises en trois versements annuels égaux à partir d’un an après l’attribution et expirent le 27 juillet 2035. Aucune action ordinaire n’a été achetée ou vendue, et la transaction est codée « A » (acquisition). Après cette attribution, Watson détient 27 266 titres dérivés, tous en propriété directe. Ce dépôt représente une attribution d’incitation en actions de routine visant à aligner les intérêts du directeur sur ceux des actionnaires. Étant donné la taille modeste par rapport au nombre d’actions de CEL-SCI, cet événement est peu susceptible d’avoir un impact significatif sur la valorisation ou la dilution à court terme.
CVM Formular 4: Am 28. Juli 2025 wurde dem Direktor Robert E. Watson 4.000 Aktienoptionen mit einem Ausübungspreis von 8,20 $ gewährt. Die Optionen werden in drei gleichen jährlichen Tranchen ab einem Jahr nach der Gewährung fällig und verfallen am 27. Juli 2035. Es wurden keine Stammaktien gekauft oder verkauft, und die Transaktion ist mit „A“ (Erwerb) codiert. Nach dieser Zuteilung hält Watson 27.266 derivative Wertpapiere, alle im direkten Eigentum. Die Meldung stellt eine routinemäßige Aktienanreizgewährung dar, die darauf abzielt, die Interessen des Direktors mit denen der Aktionäre in Einklang zu bringen. Angesichts der bescheidenen Größe im Verhältnis zur Aktienanzahl von CEL-SCI ist es unwahrscheinlich, dass dieses Ereignis eine wesentliche Auswirkung auf die Bewertung oder kurzfristige Verwässerung hat.
- None.
- None.
Insights
TL;DR: Routine 4,000-option grant; minimal dilution, neutral valuation impact.
The Form 4 shows an at-market incentive award to a non-executive director. With only 4,000 options (<0.01 % of float) at an $8.20 strike, the grant neither signals insider conviction (no open-market purchase) nor meaningfully alters capital structure. Vesting over three years promotes long-term alignment but adds immaterial potential dilution. I view the filing as administrative, not market-moving.
TL;DR: Standard board compensation practice; maintains alignment, no red flags.
Issuing options with multi-year vesting is consistent with governance best practices, encouraging director oversight continuity. Strike equals current market price, avoiding preferential terms. No accelerated vesting or unusual clauses appear. Overall, the disclosure is benign and transparent, unlikely to concern investors.
Modulo CVM 4: Il 28 luglio 2025 il direttore Robert E. Watson ha ricevuto 4.000 opzioni su azioni con un prezzo di esercizio di 8,20 $. Le opzioni maturano in tre rate annuali uguali a partire da un anno dopo la concessione e scadono il 27 luglio 2035. Non sono state acquistate o vendute azioni ordinarie, e la transazione è classificata come “A” (acquisizione). Dopo questo premio, Watson detiene 27.266 strumenti derivati, tutti di proprietà diretta. La comunicazione rappresenta una normale concessione di incentivi azionari volta ad allineare gli interessi del direttore con quelli degli azionisti. Data la dimensione contenuta rispetto al numero di azioni di CEL-SCI, l’evento probabilmente non avrà un impatto significativo sulla valutazione o sulla diluizione a breve termine.
Formulario CVM 4: El 28 de julio de 2025, el director Robert E. Watson recibió 4,000 opciones sobre acciones con un precio de ejercicio de $8.20. Las opciones se otorgan en tres cuotas anuales iguales que comienzan un año después de la concesión y vencen el 27 de julio de 2035. No se compraron ni vendieron acciones ordinarias, y la transacción está codificada como “A” (adquisición). Después de esta adjudicación, Watson posee 27,266 valores derivados, todos en propiedad directa. La presentación representa una concesión rutinaria de incentivos accionarios destinada a alinear los intereses del director con los de los accionistas. Dado el tamaño modesto en relación con el número de acciones de CEL-SCI, es poco probable que el evento tenga un impacto material en la valoración o en la dilución a corto plazo.
CVM 양식 4: 2025년 7월 28일, 이사 로버트 E. 왓슨은 행사가격 $8.20의 4,000주 스톡옵션을 부여받았습니다. 옵션은 부여일로부터 1년 후부터 3년에 걸쳐 동일한 비율로 권리가 확정되며, 2035년 7월 27일에 만료됩니다. 보통주는 매수 또는 매도되지 않았으며, 거래는 “A”(취득)로 분류됩니다. 이번 수여 이후 왓슨은 모두 직접 소유한 27,266개의 파생증권을 보유하게 되었습니다. 이 신고는 이사의 이해관계를 주주와 일치시키기 위한 일상적인 주식 인센티브 부여를 의미합니다. CEL-SCI의 주식 수에 비해 규모가 작아, 이번 사건이 평가나 단기 희석에 중대한 영향을 미칠 가능성은 낮습니다.
Formulaire CVM 4 : Le 28 juillet 2025, le directeur Robert E. Watson s’est vu attribuer 4 000 options d’achat d’actions à un prix d’exercice de 8,20 $. Les options sont acquises en trois versements annuels égaux à partir d’un an après l’attribution et expirent le 27 juillet 2035. Aucune action ordinaire n’a été achetée ou vendue, et la transaction est codée « A » (acquisition). Après cette attribution, Watson détient 27 266 titres dérivés, tous en propriété directe. Ce dépôt représente une attribution d’incitation en actions de routine visant à aligner les intérêts du directeur sur ceux des actionnaires. Étant donné la taille modeste par rapport au nombre d’actions de CEL-SCI, cet événement est peu susceptible d’avoir un impact significatif sur la valorisation ou la dilution à court terme.
CVM Formular 4: Am 28. Juli 2025 wurde dem Direktor Robert E. Watson 4.000 Aktienoptionen mit einem Ausübungspreis von 8,20 $ gewährt. Die Optionen werden in drei gleichen jährlichen Tranchen ab einem Jahr nach der Gewährung fällig und verfallen am 27. Juli 2035. Es wurden keine Stammaktien gekauft oder verkauft, und die Transaktion ist mit „A“ (Erwerb) codiert. Nach dieser Zuteilung hält Watson 27.266 derivative Wertpapiere, alle im direkten Eigentum. Die Meldung stellt eine routinemäßige Aktienanreizgewährung dar, die darauf abzielt, die Interessen des Direktors mit denen der Aktionäre in Einklang zu bringen. Angesichts der bescheidenen Größe im Verhältnis zur Aktienanzahl von CEL-SCI ist es unwahrscheinlich, dass dieses Ereignis eine wesentliche Auswirkung auf die Bewertung oder kurzfristige Verwässerung hat.
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-281887
PROSPECTUS SUPPLEMENT NO. 1
(To Prospectus Supplement dated December 6, 2024 and Prospectus dated December 2, 2024)
Up to $50,000,000
Common Stock
This Prospectus Supplement No. 1 (the “Prospectus Supplement”) amends and supplements certain information in our prospectus dated December 2, 2024 (the “Base Prospectus”) and our prospectus supplement dated December 6, 2024 (the “Prior Prospectus Supplement,” and together with the Base Prospectus, the “Prospectus”) relating to the offer and sale of shares of our common stock through Jefferies LLC (the “Agent”) as sales agent, in “at the market offerings” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, pursuant to the Open Market Sale AgreementSM (the “Sale Agreement”) with Jefferies LLC. This Prospectus Supplement should be read in conjunction with the Prospectus, and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the Prospectus. This Prospectus Supplement is not complete without, and may only be delivered or utilized in connection with, the Prospectus, and any future amendments or supplements thereto.
We have not sold any shares of common stock under the Prospectus. We are filing this Prospectus Supplement to amend the Prospectus, as of the date hereof, to update the amount of shares we are eligible to sell pursuant to the Sale Agreement from $125,000,000 to $50,000,000 from and after the date hereof. Except as modified by this Prospectus Supplement, the terms of the “at the market offering” remain unchanged, and the Sale Agreement remains in full force and effect.
Our common stock is listed on The Nasdaq Capital Market (“Nasdaq”) under the symbol “CELC.” On July 28, 2025, the last reported sale price of our common stock on Nasdaq was $36.79 per share.
Investing in our securities involves a high degree of risk. You should read the information contained in or incorporated by reference under the heading “Risk Factors” beginning on page S-6 of the Prospectus Supplement and on page 6 of the Base Prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this Prospectus Supplement or the Prospectus. Any representation to the contrary is a criminal offense.
Jefferies
The date of this prospectus supplement is July 29, 2025.
FAQ
How many options did CVM director Robert Watson receive?
What is the exercise price of the newly issued CVM options?
When do the options granted to Robert Watson vest?
Do the Form 4 transactions involve any purchase or sale of CVM common stock?
What is the total number of derivative securities Watson now owns?
